The U.S. Patent and Trademark Office (USPTO) issued two new patents requested by Pulmatrix – one for the expansion of its iSPERSE drug delivery technology and one for the expansion of protections for PUR0200, the company’s investigative candidate for chronic obstructive pulmonary disease (COPD). iSPERSE technology delivers drugs directly…
Chiesi recently completed a long-term study showing that its extra-fine, fixed-dose, triple combination inhaler Trimbow is more effective than Utibron (indacaterol and glycopyrronium) as a therapy for chronic obstructive pulmonary disease (COPD). Trimbow contains the anti-inflammatory inhaled corticosteroid (ICS) beclomethasone dipropionate and two bronchodilators, the long-acting beta2 agonist (LABA) formoterol fumarate and the…
A combination of Verona Pharma’s COPD therapy candidate RPL554 and Spiriva (tiotropium) significantly improved patients’ lung function and appeared to ease their breathing difficulties, Phase 2a clinical trial results showed. The double-blind, placebo-controlled study (NCT03028142) looked at the combo’s ability to benefit 30 people with chronic obstructive pulmonary disease. Patients received…
Pulmatrix has licensed PUR0200, its investigative inhaled treatment for people with chronic obstructive pulmonary disease (COPD), to the Vectura Group to speed its entry into the U.S. market. Vectura, a company specialized in inhaled airway products, will now be responsible for all future development costs to advance the product in the…
According to the Better Health Channel, a chest infection affects either the larger airways or the smaller air sacs of the lungs. Most chest infections are viruses, meaning that the body’s immune system is enough to fight the infection on its own. However, with most bacterial chest infections, antibiotics are needed. So…
Verona Pharma recently announced clinical development updates and interim results for the first half of 2017 for RPL554 as a treatment for chronic obstructive pulmonary disease (COPD) with the start of four new clinical trials. Verona developed RPL554 as a nebulized dual-inhibitor of the enzymes phosphodiesterase 3 and 4…
The European Union has approved Trimbow as a maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease. Trimbow, developed by Italy’s Chiesi Group, is the first triple-combination inhaler for COPD. It contains the inhaled corticosteroid beclometasone dipropionate, the β2 agonist formoterol fumarate, and the muscarinic antagonist glycopyrronium.
Verona Pharma recently dosed the first patients in its Phase 2b clinical trial evaluating RPL554 as a maintenance treatment for chronic obstructive pulmonary disease (COPD). RPL554 is a first-in-class dual inhibitor of the enzymes phosphodiesterase 3 and 4. The drug has anti-inflammatory and bronchodilator properties. An inhaled formulation of…
We know dealing with COPD sometimes feels like an uphill battle, both for the patients and the caregivers. You feel like you’re not doing enough or as if the disease is taking up all your time and attention. To help you on your journey, we’ve gathered a few quotes we thought…
There is a broad spectrum of lung diseases, which is made up of any disease that causes the lungs to not function as they should. They affect different parts of the respiratory system, including the airways, lung tissue and blood circulation. Here are a few examples of lung diseases that affect millions of…
Get regular updates to your inbox.